Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study
Summary
-
- GRACE met its primary endpoint
- Significant improvements in hypertension, hyperglycemia, and other manifestations of cortisol excess were observed throughout the treatment with relacorilant
- Due to relacorilant’s specificity for the glucocorticoid receptor and its unique mechanism of action, the observed efficacy was seen:
-
-
- Without cases of relacorilant-induced irregular vaginal bleeding with endometrial hypertrophy
- Without increases in cortisol concentrations and relacorilant-induced hypokalemia
- Without reported cases of adrenal insufficiency
- Without independently-confirmed QT prolongation
-